EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Large-scale high-throughput screen for cardiac ryanodine receptor targeted therapeutics

Roman Nikolaienko, Elisa Bovo, Jonathan C Solberg, Marzena Brinkmann, Levy M Treinen, Andrew R Thompson, Kaja Berg, David D Thomas, Jennifer J Thomas, Donald M Bers, Courtney C Aldrich, Aleksey V Zima und 2 weitere

Journal of Biological Chemistry · 2026

DOI: 10.1016/j.jbc.2025.110951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Roman Nikolaienko und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Physiology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, High-Throughput Screening Assays, Small Molecule Libraries. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In high-throughput screening (HTS) assays using fluorescence lifetime (FLT)-detected FRET, we have identified compounds that allosterically modulate the pathologically leaky ryanodine receptor (RyR) calcium release channels. These compounds may prevent or reduce the elevated Ca2+ that fuels arrhythmia, heart failure, and age-related neurodegeneration. RyRs are responsible for intracellular Ca2+ release from endoplasmic/sarcoplasmic reticulum (ER/SR). The resulting [Ca2+] pulse is a signal for many cellular processes, whereas sustained elevated [Ca2+] is pathologic. Our FRET-based HTS detects the pathology-linked RyR leaky state by monitoring binding of the accessory protein calmodulin and the DPc10 peptide (corresponding to RyR2 residues 2460-2495) known to perturb interdomain interactions within RyR2. Under conditions mimicking a pathological state, we have screened a 50,000-compound chemical library to identify small-molecule modulators of RyR2 in cardiac SR membranes. This screen yielded 603 compounds that reproducibly altered FRET. Based on FRET response profiles that align with therapeutic potential, 83 of those most promising compounds were purchased and validated by FRET dose response evaluation. Focusing on ten chemical scaffolds that desirably increase A-CaM binding, six representative compounds reduced RyR2 activity as measured by [3H]ryanodine binding. Ca2+ dynamics in HEK293 cells expressing human RyR2 or in cardiomyocytes highlighted the isoxazole group of hits as potentially therapeutic by targeting the pathological RyR2 leak state.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ryanodine Receptor Calcium Release ChannelHigh-Throughput Screening AssaysSmall Molecule LibrariesHumansFluorescence Resonance Energy TransferCalciumHEK293 CellsAnimalsCalmodulinSarcoplasmic ReticulumMyocytes, CardiacCalcium Signaling

Stichwörter der Autor:innen

biosensorcalcium channelcalcium intracellular releasecalcium leakcalmodulin (CaM)cardiomyocytedrug screeningfluorescence resonance energy transfer (FRET)high-throughput screening (HTS)isoxazole

Substanzen

Ryanodine Receptor Calcium Release ChannelCalciumCalmodulinSmall Molecule LibrariesRyR2 protein, human

Autor:innen und Institutionen

  • Department of Cell and Molecular Physiology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.
  • Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA; Photonic Pharma LLC, Minneapolis, Minnesota, USA.
  • Photonic Pharma LLC, Minneapolis, Minnesota, USA.
  • Department of Pharmacology, University of California at Davis, Davis, California, USA.

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS
  • NIAMS NIH HHS
  • National Heart Lung and Blood Institute
  • National Institute on Aging
  • National Institutes of Health
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Nikolaienko, R., Bovo, E., Solberg, J. C., Brinkmann, M., Treinen, L. M., Thompson, A. R., Berg, K., Thomas, D. D., Thomas, J. J., Bers, D. M., Aldrich, C. C., Zima, A. V., Cornea, R. L., & Rebbeck, R. T. (2026). Large-scale high-throughput screen for cardiac ryanodine receptor targeted therapeutics. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110951

Vancouver

Nikolaienko R, Bovo E, Solberg JC, Brinkmann M, Treinen LM, Thompson AR, et al. Large-scale high-throughput screen for cardiac ryanodine receptor targeted therapeutics. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2025.110951

BibTeX
@article{Nikolaienko2026,
  author = {Nikolaienko, Roman and Bovo, Elisa and Solberg, Jonathan C and Brinkmann, Marzena and Treinen, Levy M and Thompson, Andrew R and Berg, Kaja and Thomas, David D and Thomas, Jennifer J and Bers, Donald M and Aldrich, Courtney C and Zima, Aleksey V and Cornea, Razvan L and Rebbeck, Robyn T},
  title = {Large-scale high-throughput screen for cardiac ryanodine receptor targeted therapeutics},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  doi = {10.1016/j.jbc.2025.110951}
}
Kostenlos starten →